6 days Ago By ABMN Staff
Geode Capital Management LLC grew its holdings in shares of Vera Therapeutics, Inc. ( NASDAQ:VERA – Free Report ) by 14.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission.
The institutional investor owned 1,153,325 shares of the company’s stock after acquiring an additional 148,660 shares during the quarter. Geode Capital Management LLC’s holdings in Vera Therapeutics were worth $48,787,000 at the end of the most recent quarter. Other institutional investors and hedge funds have also recently made changes to their positions in the company.
AlphaQuest LLC bought a new stake in shares of Vera Therapeutics during the 4th quarter valued at approximately $34,000. Alliancebernstein L.P.
boosted its position in Vera Therapeutics by 2.0% in the fourth quarter. Alliancebernstein L.
P. now owns 40,350 shares of the company’s stock valued at $1,706,000 after buying an additional 800 shares in the last quarter. E Fund Management Co.
Ltd. grew its stake in shares of Vera Therapeutics by 22.3% during the fourth quarter.
E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock worth $262,000 after buying an additional 1,130 shares during the last quarter.
Corebridge Financial Inc. increased its holdings in shares of Vera Therapeutics by 5.8% during the fourth quarter.
Corebridge Financial Inc. now owns 22,047 shares of the company’s stock worth $932,000 after buying an additional 1,210 shares in the last quarter. Finally, KBC Group NV lifted its stake in shares of Vera Therapeutics by 127.
2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after acquiring an additional 1,387 shares during the last quarter. Institutional investors own 99.
21% of the company’s stock. Vera Therapeutics Stock Performance NASDAQ:VERA opened at $21.50 on Tuesday.
The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.
76. Vera Therapeutics, Inc. has a fifty-two week low of $18.
53 and a fifty-two week high of $51.61. The company has a 50 day simple moving average of $27.
25 and a two-hundred day simple moving average of $37.06. The company has a market capitalization of $1.
37 billion, a PE ratio of -8.24 and a beta of 1.28.
Analyst Upgrades and Downgrades A number of brokerages recently weighed in on VERA. Wolfe Research began coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $49.
00 price objective on the stock. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.
00 price target on the stock. Guggenheim raised their price objective on shares of Vera Therapeutics from $59.00 to $61.
00 and gave the company a “buy” rating in a report on Thursday, February 27th. Finally, JPMorgan Chase & Co. cut their target price on shares of Vera Therapeutics from $77.
00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the company.
According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $64.67. Read Our Latest Report on Vera Therapeutics Vera Therapeutics Company Profile ( Free Report ) Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases.
Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. See Also Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc.
( NASDAQ:VERA – Free Report ). Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
